Company overview
ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells.
News Center
-
05-172022The Phase Ib/II clinical study of IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors completed the first patient enrollment and administrationOn May 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announce......See details
-
05-102022ImmuneOnco was invited to give an oral presentation at the PEGS Boston SummitIn May 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") was invited ......See details
-
04-012022ImmuneOnco Announced Appointment of Dr. Xiaodong Gan as Senior Vice President for Clinical trialsOn April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announc......See details